[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-obstruction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-obstruction":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100541933","nxt-post-market-clinical-follow-up-100541933",false,"NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter","ALL",{"count":18,"type":19},180,"ESTIMATED","OBSERVATIONAL","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[23,24,25,26,27],"Urinary Incontinence","Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","RECRUITING","2026-05-13",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":32},"2024-06-18",{"date":36,"type":19},"2027-03",{"name":38,"class":39},"Laborie Medical Technologies Inc.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":63,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100384647","5-alpha-reductase-2-as-a-marker-of-resistance-to-5ari-therapy-100384647","NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","Inclusion Criteria:\n\n* Male (physiological);\n* Age ≥ 50;\n* Eligible for treatment with 5ARI therapy;\n* Presence of lower urinary tract symptoms secondary to BPH;\n* Prostate size \\>40cc by digital rectal examination;\n* Absence of prostate nodule, tenderness or firmness;\n* Mildly elevated PSA's \\>1.5 ng\u002Fml and ≤ 40 ng\u002Fml;\n* Undergoing clinically indicated prostate biopsy for elevated prostate-specific antigen (PSA).\n\nExclusion Criteria:\n\n* Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);\n* Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;\n* Current urinary tract infection;\n* Previous pelvic radiation;\n* Previous treatment with demethylating drugs;\n* Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;\n* Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.","MALE","50 Years",{"count":50,"type":19},120,"INTERVENTIONAL",[53],"NA","The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.",[56,57,58,59,60,61,24,62],"Benign Prostatic Hyperplasia","Prostate Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Lower Urinary Tract Symptoms","Urinary Tract Disease",[64,65],"Finasteride","5 Alpha Reductase","2025-10-27",{"date":68,"type":32},"2025-10-28",{"date":70,"type":32},"2020-09-25",{"date":72,"type":19},"2026-11-30",{"name":74,"class":75},"Beth Israel Deaconess Medical Center","OTHER",1]